OR WAIT null SECS
September 21, 2021
Combining avelumab with standard neoadjuvant chemotherapy induced pathological complete responses in over half of patients with nonmetastatic muscle-invasive bladder cancer.
September 20, 2021
Adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel may be the new standard of care for the treatment of patients with de novo metastatic castration-sensitive prostate cancer.
Patients had received at least 1 novel hormonal agent and had non-progressive disease after subsequent treatment with taxane-based therapy.
September 19, 2021
"2 years of abiraterone-based therapy significantly improves metastasis-free survival and overall survival of high-risk nonmetastatic prostate cancer starting androgen deprivation therapy and should be now considered a new standard of care,” said Gerhardt Attard, MD, FRCP, PhD.
There was limited clinical activity with the combination in patients with HRD-negative tumors.
Sabizabulin was well tolerated and associated with significant and durable objective tumor responses in patients with metastatic castration resistant prostate cancer.
Unadjusted real-world overall survival was longer in patients receiving first-line cisplatin compared with patients receiving other first-line treatments.
The results included data for 132 patients, all of whom had prior enzalutamide and/or abiraterone acetate.
September 18, 2021
"The promising rPFS and overall survival data support further evaluation of pembrolizumab plus olaparib in molecularly unselected patients with mCRPC who received prior docetaxel treatment,” the authors concluded.
The hard-to-treat subgroups consisted of age 65 years or older, presence of liver metastasis, primary upper tract disease, and nonresponse to prior PD-1/L1 inhibitor treatment.
